Am Fam Physician. 2005 Jul 1;72(01).
to the editor: I am grateful for the thorough review of osteoporosis in the article “Pharmacologic Prevention of Osteoporotic Fractures,”1 that appeared in American Family Physician. However, there was no mention of the possible protective effects of hydrochlorothiazide (HydroDIURIL). Numerous references2-4 are available that cite increased bone density of patients receiving this medication, which is likely a result of its inhibition of calciuria.
Retrospective control-matched studies suggest a lowering of hip fracture incidence with the use of this medication.3,5 However, we will probably never see an example of the gold standard placebo-controlled, double-blind study for this medication, because nobody will ever make any money as a result of conducting such a study. Nevertheless, the evidence is there, the medication is inexpensive, and this information deserves at least a mention in a review article1 of this kind.
REFERENCESshow all references
1. Zizic TM. Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 2004;70:1293-300. ...
2. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;133:516-26.
3. Cauley JA, Cummings SR, Seeley DG, Black D, Browner W, Kuller LH, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 1993;118:666-73.
4. Sigurdsson G, Franzson L. Increased bone mineral density in a population-based group of 70-year-old women on thiazide diuretics, independent of parathyroid hormone levels. J Intern Med 2001;250:51-6.
5. Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003;139:476-82.
in reply: Dr. Wagman’s points concerning the ability of hydrochlorothiazide to increase bone mineral density are relevant. Retrospective, control-matched studies do suggest a lowering of hip fracture incidence with the use of thiazide diuretics. However, the purpose of our article1 was not to provide an in-depth examination of the full gamut of treatments for osteoporosis, but rather to focus on the most relevant treatment options.
1. Zizic TM. Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 2004;70:1293-300.
Send letters to firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions